Leerink Partnrs Forecasts Xencor’s Q2 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for shares of Xencor in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst J. Chang now forecasts that the biopharmaceutical company will earn ($0.77) per share for the quarter, down from their prior forecast of ($0.66). The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Xencor’s Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.88) EPS and FY2026 earnings at ($3.24) EPS.

Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. William Blair started coverage on shares of Xencor in a research note on Monday, April 21st. They issued an “outperform” rating for the company. Wedbush restated an “outperform” rating and set a $31.00 price target on shares of Xencor in a research report on Wednesday, April 30th. Barclays lowered their target price on Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research note on Thursday, May 8th. Finally, Wells Fargo & Company reduced their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Xencor Trading Down 7.5%

Shares of XNCR opened at $8.11 on Monday. Xencor has a 1-year low of $7.16 and a 1-year high of $27.24. The firm’s 50 day simple moving average is $10.63 and its 200 day simple moving average is $17.52. The company has a market capitalization of $577.04 million, a P/E ratio of -2.53 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. During the same quarter in the prior year, the company earned ($1.11) earnings per share. Xencor’s revenue was up 104.6% compared to the same quarter last year.

Insider Activity at Xencor

In other news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the sale, the executive vice president now owns 49,169 shares of the company’s stock, valued at approximately $542,334.07. The trade was a 8.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.76% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Barclays PLC increased its stake in shares of Xencor by 100.7% in the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after acquiring an additional 78,066 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Xencor by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 130,354 shares of the biopharmaceutical company’s stock valued at $2,621,000 after acquiring an additional 3,635 shares during the period. GAMMA Investing LLC raised its position in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 508 shares during the period. KBC Group NV raised its holdings in Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 813 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Xencor by 24.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,839 shares of the biopharmaceutical company’s stock valued at $341,000 after acquiring an additional 2,946 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.